Improving heart failure outcomes: EMPEROR-Reduced trial

Watch Professor Andrew Coats and Professor Faiez Zannad as they discuss key findings from the EMPEROR-Reduced Phase III trial, which looks at the association between empagliflozin and improved cardiovascular outcomes in heart failure patients with reduced ejection fraction (HFrEF), with and without diabetes.

Topic

The EMPEROR-Reduced trial is a phase III randomised, double-blind trial that aims to evaluate the efficacy and safety of empagliflozin compared with placebo in patients with chronic heart failure with HFrEF, with and without diabetes mellitus (DM). This 30-minute journal club will explore the insights and impact of the recent primary endpoint results of the EMPEROR-Reduced trial presented at the European Society of Cardiology (ESC) Congress 2020.

Target audience

This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in heart failure management.

Learning objectives

• Describe the mechanism of action of empagliflozin and its therapeutic value in the management of cardio-renal-metabolic conditions
• Recall why empagliflozin is effective in reducing mortality risk in heart failure patients, with and without DM2
• Explain the impact of empagliflozin on hospitalisation rates for heart failure patients, with and without DM2

Accreditation

An accreditation application has been submitted for this Journal Club to the Royal College of Physicians (RCP) and is currently under review.